This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Event Highlights

December 15 - 18, 2024
Marriott Marquis San Diego,
Live In-Person Event: December 15 - 18, 2024

It all comes together in San Diego with 5 Days of Content, 15 Tracks, 13 Scientific Briefings and 3 Pre-conference Workshops

What Will You Learn?

Learn how to engineer antibody therapeutics with improved drug-like properties to better combat a variety of diseases and to gain a competitive advantage over existing therapeutics already on the market at:

  • Track 1: Immunogenicity
  • Track 2: Antibody Developability

Find Novel Targets and Discovery Strategies to Develop Antibody, Antibody-Like and Protein Therapeutics at:

  • Pre-conference workshop: Next-Generation Sequencing for Antibody Library Analysis and Monocloncal Discovery and Engineering – Sunday
  • Novel Methods to Interrogate Receptors as Targets – Monday
  • Libraries, Display, Selection and Screening – Wednesday

Decide which therapeutic modality (antibody therapeutic, bispecific, fusion protein, antibody alternative, ADC, CAR-T etc.) will give you the greatest chance of success in developing new therapeutics at:

  • CAR-T Cell Recruitment in Solid Tumors – Tuesday
  • Preclinical and Clinical Antibodies in Development – Friday
  • Clinical Stories: Antibodies in Development - Friday

Learn how to manipulate the immune system to develop novel therapeutics at:

  • Pre-conference workshop: Immuno-engineering: Bridging the Immune System and Antibody Therapeutics – Sunday
  • Meeting Challenges for Antibody Therapies in the Tumor Microenvironment - Tuesday
  • Clonal Expansion of Lymphocytes in Immune Repertoire - Wednesday

Find new disease applications of antibody therapeutics beyond cancer at:

  • Novel Indications for Therapeutic Antibodies - Tuesday
  • Engineering & Application  of Therapeutic Antibodies  for Neurodegenerative Diseases – Tuesday
  • Vaccines and Antibodies in Infectious Diseases – Wednesday

Discover New Frontiers in Novel Therapeutic Development at:

  • Microbiome Therapeutics – Wednesday
  • Innovating Antibody Therapeutics - Thursday


Chairperson: Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, Switzerland

Clinically Important Receptors and Techniques for Interrogating Them

Ira Mellman, Ph.D., Vice President, Cancer Immunology, Genentech

More Than Blocking Ligands: Designing Therapeutic Proteins to Surface Receptors

Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, Switzerland

Decoding Ligand Receptor Interactions

Bernd Wollscheid, Ph.D., Professor, Chemical & Systems Biology, Institute of Molecular Systems Biology and Department of Health Sciences and Technology (D-HEST), ETH Zurich, Switzerland
Laura P.W. Ranum, Ph.D., Director, Center for NeuroGenetics, Kitzman Family Professor of Molecular Genetics and Microbiology, College of Medicine, University of Florida

Pathology From the Molecular Scale On Up

Garry P. Nolan, Ph.D., Rachford and Carlota A. Harris Professor, Department of Microbiology & Immunology, Baxter Laboratory for Stem Cell Biology, Stanford University School of Medicine

Emerging Approaches to Modulate Receptor Function in Stem Cells

Rami Hannoush, Ph.D., Principal Scientist & Group Leader, Early Discovery Biochemistry, Genentech

xPloration™: A Platform Enabling High-throughput Functional Screening of Antibody Libraries

Jennifer Cochran, Ph.D., Associate Professor, Bioengineering & Chemical Engineering, Stanford University and Co-Founder and Chairman, xCella Biosciences


Session Chair: Paul J. Carter, Ph.D., Senior Director and Staff Scientist, Antibody Engineering, Genentech, Inc.

From Format to Function - Transformative Antibody Therapeutics

Martin Steegmaier, Ph.D., Head of Discovery, Large Molecule Research, Roche pRED, Roche Innovation Center Munich, Germany

Agonizing the TNFR Superfamily for Cancer Immunotherapy

Greg Lazar, Ph.D., Director and Senior Scientist, Antibody Engineering, Genentech

Adapted Fc-glycan Changes for Enhanced ADCC and/or CDC

Gestur Vidarsson, Ph.D., Head of Immunoglobulin Research/PI, Experimental Immunohematology,    Sanquin Research, The Netherlands


Session Co-Chairs:

  • Trudi Veldman Ph.D., Senior Director Biologics, AbbVie Bioresearch Center
  • Chung-Ming Hsieh, Executive Director, Biologics Discovery Boston, Merck Research Laboratories
SKY59: Novel Recycling Antibody against C5 with Improved Pharmacokinetics for the Treatment of Complement-mediated Diseases

Kenta Haraya, Ph.D., Scientist, Research Division, Biologics Discovery, Chugai Pharmaceutical Co Ltd., Japan

Novel Effector Function Attenuating Mutations That Maintain Antibody Stability and Reduce Toxicity

James A. Ernst, Ph.D., Senior Scientist & Group Leader, Department of Protein Sciences, Genentech

Antibody Optimization for Treg Depletion in Cancer Therapy

Frederick Arce Vargas, M.D. Ph.D., Research Associate, University College London Cancer Institute, United Kingdom

Selective FcγR Engagement by Agonistic Anti-CD40 Abs

Rony Dahan, Ph.D., Principal Investigator, Department of Immunology, Weizmann Institute of Science, Israel

Potent Antitumor Activity of IL2-Fc Requires Fc-mediated Depletion of Tregs

Daniel Christ, Ph.D., Associate Professor and Head Antibody Therapeutics, Director Centre for Targeted Therapy, Immunology Program, Garvan Institute of Medical Research


Session Co-Chairs:

  • Dennis R. Burton, Ph.D., Professor, Department of Immunology and Microbial Science, The Scripps Research Institute
  • Paul Parren, Ph.D., Senior Vice President and Scientific Director, Genmab, The Netherlands
Fc Fucosylation and Sialylation and Antibody Effector Function

Jeffrey Ravetch, Ph.D., Professor, Rockefeller University

Sulfation of Broadly Neutralizing HIV Antibodies

Raiees Andrabi, Research Associate, The Burton Lab,The Scripps Research InstitutePRELIMINARY AGENDA 

Integrative Mass Spectrometric Structural Analysis of Glycoprotein Therapeutics and Its Usage to Evaluate and Score Biosimilarity

Albert J. R. Heck, Ph.D., Professor and Science Faculty, Utrecht University, The Netherlands

Post-translational Modification of Antibodies in Rheumatoid Arthritis

Leendert A. Trouw Ph.D., Assistant, Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden,The Netherlands

Regulation of Autoantibody Activity by the IL-23–TH17 Axis and its Impact on Autoimmune Disease

Gerhard Krönke, M.D., Professor of Translational Immunology, Department of Internal Medicine 3, Institute of Rheumatology and Immunology, University of Erlangen-Nuremberg Germany


Session Chair:

  • James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development

SIMPLE Antibody™ Platform Generates Unique Species Cross-reactive Antibodies against Immune Checkpoints

Erik Hofman, Ph.D., Senior Scientist, Research Department, Argenx, Belgium 

Immuno-oncology and Prostate Cancer

Xin Lu, Professor M.D., University of Notre Dame

A Novel Cytokine Receptor Agonistic Antibody by Design

Cheng-I Wang, Ph.D., Senior Principal Investigator, Singapore Immunology Network, Biomedical Sciences Institutes, ASTAR, Singapore

Boosting Cancer Immunotherapy with Combined Immunomodulatory Drugs

Mickey Hu, Ph.D., Scientist, Panorama Institute of Molecular Medicine

Cow Ultralong CDR3 Antibodies Targeting Exhausted T-cells

Vaughn Smider M.D., Ph.D., Associate Professor, Molecular Medicine, The Scripps Research Institute


Session Co-Chairs:

  • Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, United Kingdom
  • Janine Schuurman, Ph.D., Vice President, Research, Genmab, The Netherlands
Protia – Bispecific T-Cell Engagers Designed for Local Activation in the Tumor Environment

Volker Schellenberger, Ph.D., CEO and President, Amunix

Immuno-Viral Therapy for Solid Tumors

Maria Navarro, M.D., Project & Operations Manager, Icell Kealex Therapeutics

Costimulation of Immune Cells in the Tumor Microenvironment via Bispecific DART® and TRIDENT™ Molecules

Syd Johnson, Ph.D., Vice President, Antibody Engineering, MacroGenics

Harnessing Fc Gamma Receptor Biology to Optimize Antibodies Targeting TNFR Superfamily Members

Nick Wilson, Ph.D., Executive Director of Immuno-modulatory Drug Discovery, Agenus

mRNA Vaccination and Combination Therapy with Immunomodulating Antibodies

Sebastian Kreiter, Head, Tron/BioNTech, Germany

An Update on the Darzalex Story

Kate Sasser, Ph.D., Vice President, Head of Oncology Translational Research, Janssen


Session Co-Chairs:

  • Paul J. Carter, Ph.D., Senior Director and Staff Scientist, Antibody Engineering, Genentech, Inc.
  • Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, Switzerland

Bacterial Secretion Systems

Thomas Marlovits, Professor, Institute of Molecular Pathology, Austria

Nanobodies as Inhaled Biotherapeutics for Lung Diseases, with ALX-0171 (anti-RSV) as a Case Study

Antonin De Fourgerolles, Ph.D., Chief Scientific Officer, Ablynx, Belgium

Bispecific Antibodies Targeting Transfer in Receptor or CD98 to Facilitate Delivery Across the Blood Brain Barrier

Jasi Atwal, Scientist, Genentech

Artificial Immunotoxins

Ernst Wagner, Ph.D., Chair, Pharmaceutical Biotechnology, Center for System-based Drug Research, Center for Nanoscience, Ludwig Maximilians University, Germany


Session Chair:

  • Gregory Adams, Ph.D., Chief Scientific Officer, Eleven Biotherapeutics
Redox Selenium ADCs Improve Cancer Cell Monoclonal Antibody Cytotoxicity

Julian Spallholz, Ph.D., Professor, Nutritional Sciences,Texas Tech University

Antibody-Drug Conjugates for Treating Steroid-Resistant Malignancies and Autoimmune Diseases

Masahiro Yasunaga, M.D., Ph.D., Unit Leader, Developmental Therapeutics,National Cancer Center, Japan

Targeting Tumors and Their Vasculature with Antibody-Drug Conjugates

Dimiter Dimitrov, Ph.D., Senior Investigator, CCR, Cancer and Inflammation Program, NCI-Frederick, NIH

Novel Calicheamicin Antibody-Drug Conjugates

Julia Gavrilyuk, Ph.D., Principal Scientist, Discovery Chemistry, Abbvie Stemcentrx


Session Chair:

Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica

Using Next Generation Sequencing in Antibody Libraries

Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica

Quantitative Proteomics

Jim Wells, Professor, UCSF

Engineering Developable Antibodies

Peter Tessier, Professor, Rensselaer Polytechnic Institute

Programming Antibodies and Antigens using Deep Sequencing-Enabled Protein Engineering

Tim Whitehead, Ph.D., Associate Professor, Chemical Engineering and Materials Science, Michigan State University

Advances in Yeast Display Selections for Membrane Targets

Benjamin Hackel, Ph.D., Assistant Professor, Chemical Engineering and Materials Science, University of Minnesota

Functional Interrogation and Mining of Natively Paired Heavy:Light Human Antibody Repertoires

Department of Pharmaceutical Chemistry, The University of Kansas


Session Chair: Jamie K. Scott, M.D., Ph.D., Professor and Canada Research Chair in Molecular Immunity, Department of Molecular Biology & Biochemistry and Faculty of Health Sciences, Simon Fraser University, Canada

Genetic Variation in MHC Proteins is Associated with T-cell Receptor Expression Biases

Eilon Sharon, Ph.D., Postdoctoral Fellow, Howard Hughes Medical Institute, Stanford University

CD8 T-cell Repertoire Dynamics and Their Association with HCV Clearance

Naglaa H. Shoukry, Ph.D., Associate Professor, Department of Medicine, University of Montreal, Canada

CD39 and CD103 Identify Tumor-reactive CD8 T-cells in Human Solid Tumors

Thomas Duhen, Ph.D., Senior Research Scientist, AgonOx


Session Chair: K. Dane Wittrup, Ph.D., C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

Tumor Targeting Antibodies: Distinct Innate and Adaptive Immune Sensing

Yang-Xin Fu, M.D., Ph.D., Professor of Pathology, Mary Nell and Ralph B. Rogers Professorship in Immunology, UT Southwestern

Innate and Adaptive Integrin-targeted Combination Immunotherapy

Jennifer R. Cochran, Ph.D., Co-Founder and Director, Nodus Therapeutics

NK Cell Engagement with Bispecific Antibodies

Ann Cheung, Ph.D., Director of Biology, Dragonfly Therapeutics

Anti-chaperone Antibodies in Cancer Therapy    

Amy S. Lee, Ph.D., Associate Director for Basic Research, USC Norris Comprehensive Norris Cancer Center and Professor of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California


Session Chair: James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development

Therapeutic Antibodies that Silence B Cells by Emulating Peripheral Immune Tolerance

John Cambier Ph.D., Distinguished Professor and Chair, Department of Immunology and Microbiology, University of Colorado SOM

Antibody Approaches to T1D

William Ridgway, Professor, University of Cincinnati

Action of Bispecific Anti-FGFR1/βKlotho Antibody in Obese Mice and Humans

Junichiro Sonoda, Ph.D., Senior Scientist, Cancer Immunology, Genentech


Session Chair: Paul Parren, Ph.D., Senior Vice President and Scientific Director, Genmab, The Netherlands

Evolution of Antibodies of Different Germline Gene Origins Proceed through Different Paths

Mats Ohlin, Ph.D., Professor, Department of Immunotechnology & SciLifeLab, Lund University, Sweden

DNA-based Antibody Therapy via Antibody Gene Transfer

Kevin Hollevoet, Ph.D., Group Leader and Postdoc, Therapeutic and Diagnostic Antibodies, University of Leuven, Belgium

Structural Determinants for Modulating Antibody-Fc Receptor Interactions for Half-Life Enhancement and Effector Functions

Karthik Viswanathan, Ph.D., Director, Research, Visterra, Inc.